| 國立成功大學 |
2023 |
Na-Intercalation Compounds and Na-Ion Batteries
|
Chung, H.-C.;Li, W.-B.;Wang, Y.-M.;Lin, M.-F. |
| 國立成功大學 |
2023 |
Energy Resources and Challenges
|
Nguyen, T.D.H.;Li, W.-B.;Dien, V.K.;Han, N.T.;Chung, H.-C.;Lin, S.-Y.;Thuan, L.V.P.;Tran, N.T.T.;Shih, J.-H.;Lin, M.-F. |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial
|
Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; Chia-Chi Lin; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
|
Chia-Chi Lin; Doi T.; Muro K.; Hou M.-M.; Esaki T.; Hara H.; Chung H.C.; Helwig C.; Dussault I.; Osada M.; Kondo S. |
| 臺大學術典藏 |
2022-09-15T01:08:45Z |
Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
|
Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; Chia-Chi Lin; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. |
| 臺大學術典藏 |
2022-08-19T06:48:44Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Hsu C.-H.; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N.; Chao Y.; Chen J.-S.; Bang Y.-J.; Bendell J.; Lee K.-H.; Wang Y.; Abdullah H.; Liu B.; Spahn J.; Hack S.P.; Verret W.; CHIH-HUNG HSU; Lee M.S. |
| 臺大學術典藏 |
2022-08-19T00:20:33Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Tebbutt N.; Strickler J.; Stein S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Gane E.; George B.; He A.R.; Hochster H.; CHIUN HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Dev A.; Davis S.L.; Chung H.C.; Chen J.-S.; Chao Y.; Bendell J.; Bang Y.-J.; Lee K.-H.; He A.R.; Wang Y.; Liu B.; Abdullah H.; Hack S.P.; Spahn J.; Lee M.S.; Ryoo B.-Y.; Hsu C.-H.; Numata K.; Stein S.; Verret W. |
| 臺大學術典藏 |
2022-05-13T08:05:07Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chung H.-C.; JANN-TAY WANG; Sun H.-Y.; Wang J.-L.; Lo Y.-C.; Sheng W.-H.; Hsieh S.-M.; Fang C.-T.; Hsueh P.-R.; Chen Y.-C.; Chang S.-C. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. |
| 臺大學術典藏 |
2022-01-05T03:36:40Z |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
|
Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2022-01-05T03:36:39Z |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. |
| 國立成功大學 |
2022 |
Compact and robust 2 � 2 fast quasi-adiabatic 3-dB couplers on SOI strip waveguides
|
Hung, Y.-J.;Jr;Chen, Chen C.-H.;Lu, G.-X.;Liang, F.-C.;Chung, H.-C.;Tseng, S.-Y. |
| 國立成功大學 |
2022 |
Compact polarization-independent quasi-adiabatic 2�2 3 dB coupler on silicon
|
Chung, H.-C.;Chen, Chen C.-H.;Hung, Y.-J.;Tseng, S.-Y. |
| 國立成功大學 |
2022 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr
|
Kang, Y.-K.;Chen, L.-T.;Ryu, M.-H.;Oh, D.-Y.;Oh, S.C.;Chung, H.C.;Lee, K.-W.;Omori, T.;Shitara, K.;Sakuramoto, Sakuramoto S.;Chung, I.-J.;Yamaguchi, K.;Kato, Kato K.;Sym, Sym S.J.;Kadowaki, S.;Tsuji, K.;Chen, J.-S.;Bai, L.-Y.;Oh, S.-Y.;Choda, Y.;Yasui, H.;Takeuchi, K.;Hirashima, Y.;Hagihara, S.;Boku, N. |
| 國立成功大學 |
2022 |
Ultra-broadband Silicon Polarization Independent 3-dB Coupler using Multi-parameter Adiabaticity Engineering
|
Chung, H.-C.;Tseng, S.-Y. |
| 臺大學術典藏 |
2021-12-01T06:02:57Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chung H.-C.; Wang J.-T.; Sun H.-Y.; Wang J.-L.; Lo Y.-C.; Sheng W.-H.; Hsieh S.-M.; Fang C.-T.; Hsueh P.-R.; YEE-CHUN CHEN; Chang S.-C. |
| 臺大學術典藏 |
2021-09-01T01:53:43Z |
Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial
|
ANN-LII CHENG; Kang Y.-K.; Lin D.-Y.; Park J.-W.; Kudo M.; Qin S.; Chung H.-C.; Song X.; Xu J.; Poggi G.; Omata M.; Lowenthal S.P.; Lanzalone S.; Yang L.; Lechuga M.J.; Raymond E. |
| 臺大學術典藏 |
2021-07-26T09:44:38Z |
Digging and burying of hosts by a pupal parasitoid
|
Chung H.-C;Okuyama T.; Chung H.-C; Okuyama T.; TOSHINORI OKUYAMA |
| 臺大學術典藏 |
2021-05-06T01:52:41Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chung H.-C.; Wang J.-T.; Sun H.-Y.; Wang J.-L.; Lo Y.-C.; Sheng W.-H.; Hsieh S.-M.; Fang C.-T.; Hsueh P.-R.; YEE-CHUN CHEN; Chang S.-C. |
| 臺大學術典藏 |
2021-05-03T02:21:02Z |
MiR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4
|
Chen H.-Y.; Lin Y.-M.; Chung H.-C.; Lang Y.-D.; Lin C.-J.; Huang J.; Wang W.-C.; Lin F.-M.; Chen Z.; Huang H.-D.; Shyy J.Y.-J.; JIN-TUNG LIANG; Chen R.-H. |
| 臺大學術典藏 |
2021-04-20T03:46:19Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chung H.-C.; Wang J.-T.; Sun H.-Y.; Wang J.-L.; Lo Y.-C.; Sheng W.-H.; Hsieh S.-M.; CHI-TAI FANG; Hsueh P.-R.; Chen Y.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-02-26T02:00:17Z |
Clinical experience of 17 cases of imported malaria at a Taiwan university hospital, 1999-2005
|
Chung H.-C.;Wang J.-T.;Sun H.-Y.;Wang J.-L.;Lo Y.-C.;Wang-Huei Sheng;Hsieh S.-M.;Fang C.-T.;Hsueh P.-R.;Chen Y.-C.;Chang S.-C.; Chung H.-C.; Wang J.-T.; Sun H.-Y.; Wang J.-L.; Lo Y.-C.; WANG-HUEI SHENG; Hsieh S.-M.; Fang C.-T.; Hsueh P.-R.; Chen Y.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-02-19T06:52:27Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Chih-Hung Hsu;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chih-Hung Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; CHIH-HUNG HSU; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; CHIH-HUNG HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chiun Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Chiun Hsu; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 臺大學術典藏 |
2021-02-02T00:46:39Z |
A Cullin3-KLHL20 Ubiquitin Ligase-Dependent Pathway Targets PML to Potentiate HIF-1 Signaling and Prostate Cancer Progression
|
Yuan W.-C. ;Lee Y.-R. ;Huang S.-F. ;Lin Y.-M. ;Chen T.-Y. ;Chung H.-C. ;Tsai C.-H. ;Chen H.-Y. ;Chiang C.-T. ;Lai C.-K. ;Lu L.-T. ;Chen C.-H. ;Gu D.-L. ;Yeong-Shiau Pu ;Jou Y.-S. ;Lu K. ;Hsiao P.-W. ;Shih H.-M. ;Chen R.-H.; Yuan W.-C.; Lee Y.-R.; Huang S.-F.; Lin Y.-M.; Chen T.-Y.; Chung H.-C.; Tsai C.-H.; Chen H.-Y.; Chiang C.-T.; Lai C.-K.; Lu L.-T.; Chen C.-H.; Gu D.-L.; YEONG-SHIAU PU; Jou Y.-S.; Lu K.; Hsiao P.-W.; Shih H.-M.; Chen R.-H. |
